表紙
市場調査レポート

製薬企業トップ12社の契約実績レビュー・将来の戦略

Review of the Dealmaking Performance and Future Strategies of the Top 12 Pharmaceutical Companies

発行 IMS World Publications Ltd. 商品コード 253537
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
製薬企業トップ12社の契約実績レビュー・将来の戦略 Review of the Dealmaking Performance and Future Strategies of the Top 12 Pharmaceutical Companies
出版日: 2012年09月30日 ページ情報: 英文

当商品の販売は、2016年08月25日を持ちまして終了しました。

概要

当レポートでは、世界の製薬企業トップ12社のM&Aおよびライセンシング契約活動について調査・比較しており、M&A・ライセンシング契約活動に関する主要データの分析とランキング、ライセンシングの主な治療分野、開発の初期段階または後期段階製品に重点を置く企業、契約条件・構造、最も高額・最大の先行投資額を支払ったライセンシング契約などをまとめ、概略下記の内容でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 製薬企業トップ12社の全体的な契約活動

  • M&A契約活動
  • ライセンシング活動
  • ライセンシング活動の比較:開発段階別
  • ライセンシング活動の比較:治療分野別

第3章 Pfizer

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
    • 主なM&A契約
    • その他のM&A契約
  • ライセンシング戦略・契約構造
    • 企業の契約とそのピアグループの比較法
    • 治療分野への集中度:売上別
    • 契約における主要治療分野
    • 治療分野上位の総額・先行投資平均額
    • 短期的および長期的契約投資の比較

第4章 Sanofi

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第5章 Novartis

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第6章 GlaxoSmithKline

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第7章 Roche

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第8章 AstraZeneca

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第9章 Merck & Co.

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第10章 Johnson & Johnson

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第11章 Eli Lilly

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第12章 Abbott

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第13章 Bristol-Myers Squibb

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

第14章 Bayer

  • 主要事業・治療分野
  • 契約の概要
  • M&A活動
  • ライセンシング戦略・契約構造

図表

目次
Product Code: ISBN 978-0-9568270-8-1

PharmaDeals Review of the Dealmaking Performance and Future Strategies of the Top 12 Pharmaceutical Companies compares the top pharma companies according to their M&A and licensing deal activities and help you understand their strategic intent.

Review of the Dealmaking Performance and Future Strategies of the Top 12 Pharmaceutical Companies.

Equip your team with business critical information, deal insight and key data on M&A and licensing deal activities of the top 12 pharma companies. The report is based on PharmaDeals Agreements database, which is trusted by the world's largest pharma companies.

Buy this Report to find out about:

  • The top 12 pharma companies' ranking in terms of their M&A and licensing activities - who are the most active and least active dealmakers overall
  • What are the leading therapy areas for licensing by the top 12 pharma companies
  • Which companies focus on licensing early-stage or late-stage products
  • What deal terms and structures the top 12 pharma companies agree to complete the deal
  • Which licensing deals received the highest deal values and largest upfront payments

Features of the Interactive iReport format provides:

  • Full report searchability: search and export text, tables and figures for your own analysis
  • Presentation-ready tables and graphics
  • Links to the PharmaDeals Database to the complete deal record
  • Access to the data with over 1,000 M&A and licensing deals of the top 12 companies with financial information where available

Table of Contents

Executive Summary

1. Introduction

  • 1.1. Overview of the Industry
  • 1.2. Overview of the Report

2. Overall Deal Activity of the Top 12 Pharma Companies

  • 2.1. M&A Deal Activity of the Top 12 Companies
    • 2.1.1. Leading Companies in M&A Dealmaking
    • 2.1.2. Company Comparison of M&A Deal Values
  • 2.2. Licensing Activity of the Top 12 Companies
    • 2.2.1. Licensing Deals: 5 Year Total and Average Deal Values
    • 2.2.2. Licensing Deals: 5 Year Total and Average Upfront Payments
    • 2.2.3. Are Licensing Activities Adequate to Defend the Patent Cliff Challenge?
    • 2.2.4. How do Licensing Activities Compare Relative to Sales
  • 2.3. Comparing Licensing Activity by Development Phase of the Top 12 Companies
    • 2.3.1. Discovery and Preclinical Stage Deals Dominate Deal Activity
    • 2.3.2. Analysis of Early-, Mid- and Late-Stage Dealmaking of the Top 12 Companies
    • 2.3.3. Competition for Late Stage Deals Drives Deal Values
  • 2.4. Comparing Licensing Activity by Therapeutic Area of the Top 12 Companies
    • 2.4.1. Most Popular Therapy Areas in Dealmaking

3. Pfizer

  • 3.1. Key Business and Therapy Areas
  • 3.2. Overview of Dealmaking
  • 3.3. M&A Activity
    • 3.3.1. Key M&A Deals
    • 3.3.2. Other Key M&A Deals
  • 3.4. Licensing Strategy and Deal Structures
    • 3.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 3.4.2. Therapy Area Focus by Sales
    • 3.4.3. Leading Therapy Areas in Dealmaking
    • 3.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 3.4.5. Comparison of Short- and Long-Term Deal Investment

4. Sanofi

  • 4.1. Key Business and Therapy Areas
  • 4.2. Overview of Dealmaking
  • 4.3. M&A Activity
    • 4.3.1. Key M&A Deals
    • 4.3.2. Other Key M&A Deals
  • 4.4. Licensing Strategy and Deal Structures
    • 4.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 4.4.2. Therapy Area Focus by Sales
    • 4.4.3. Leading Therapy Areas in Dealmaking
    • 4.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 4.4.5. Comparison of Short- and Long-Term Deal Investment

5. Novartis

  • 5.1. Key Business and Therapy Areas
  • 5.2. Overview of Dealmaking
  • 5.3. M&A Activity
    • 5.3.1. Key M&A Deals
    • 5.3.2. Other Key M&A Deals
  • 5.4. Licensing Strategy and Deal Structures
    • 5.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 5.4.2. Therapy Area Focus by Sales
    • 5.4.3. Leading Therapy Areas in Dealmaking
    • 5.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 5.4.5. Comparison of Short- and Long-Term Deal Investment

6. GlaxoSmithKline

  • 6.1. Key Business and Therapy Areas
  • 6.2. Overview of Dealmaking
  • 6.3. M&A Activity
    • 6.3.1. Key M&A Deals
    • 6.3.2. Other Key M&A Deals
  • 6.4. Licensing Strategy and Deal Structures
    • 6.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 6.4.2. Therapy Area Focus by Sales
    • 6.4.3. Leading Therapy Areas in Dealmaking
    • 6.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 6.4.5. Comparison of Short- and Long-Term Deal Investment

7. Roche

  • 7.1. Key Business and Therapy Areas
  • 7.2. Overview of Dealmaking
  • 7.3. M&A Activity
    • 7.3.1. Key M&A Deals
    • 7.3.2. Other Key M&A Deals
  • 7.4. Licensing Strategy and Deal Structures
    • 7.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 7.4.2. Therapy Area Focus by Sales
    • 7.4.3. Leading Therapy Areas in Dealmaking
    • 7.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 7.4.5. Comparison of Short- and Long-Term Deal Investment

8. AstraZeneca

  • 8.1. Key Business and Therapy Areas
  • 8.2. Overview of Dealmaking
  • 8.3. M&A Activity
    • 8.3.1. Key M&A Deals
    • 8.3.2. Other Key M&A Deals
  • 8.4. Licensing Strategy and Deal Structures
    • 8.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 8.4.2. Therapy Area Focus by Sales
    • 8.4.3. Leading Therapy Areas in Dealmaking
    • 8.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 8.4.5. Comparison of Short- and Long-Term Deal Investment

9. Merck & Co.

  • 9.1. Key Business and Therapy Areas
  • 9.2. Overview of Dealmaking
  • 9.3. M&A Activity
    • 9.3.1. Key M&A Deals
    • 9.3.2. Other Key M&A Deals
  • 9.4. Licensing Strategy and Deal Structures
    • 9.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 9.4.2. Therapy Area Focus by Sales
    • 9.4.3. Leading Therapy Areas in Dealmaking
    • 9.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 9.4.5. Comparison of Short- and Long-Term Deal Investment

10. Johnson & Johnson

  • 10.1. Key Business and Therapy Areas
  • 10.2. Overview of Dealmaking
  • 10.3. M&A Activity
    • 10.3.1. Key M&A Deals
    • 10.3.2. Other Key M&A Deals
  • 10.4. Licensing Strategy and Deal Structures
    • 10.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 10.4.2. Therapy Area Focus by Sales
    • 10.4.3. Leading Therapy Areas in Dealmaking
    • 10.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 10.4.5. Comparison of Short- and Long-Term Deal Investment

11. Eli Lilly

  • 11.1. Key Business and Therapy Areas
  • 11.2. Overview of Dealmaking
  • 11.3. M&A Activity
    • 11.3.1. Key M&A Deals
    • 11.3.2. Other Key M&A Deals
  • 11.4. Licensing Strategy and Deal Structures
    • 11.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 11.4.2. Therapy Area Focus by Sales
    • 11.4.3. Leading Therapy Areas in Dealmaking
    • 11.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 11.4.5. Comparison of Short- and Long-Term Deal Investment

12. Abbott

  • 12.1. Key Business and Therapy Areas
  • 12.2. Overview of Dealmaking
  • 12.3. M&A Activity
    • 12.3.1. Key M&A Deals
    • 12.3.2. Other Key M&A Deals
  • 12.4. Licensing Strategy and Deal Structures
    • 12.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 12.4.2. Therapy Area Focus by Sales
    • 12.4.3. Leading Therapy Areas in Dealmaking
    • 12.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 12.4.5. Comparison of Short- and Long-Term Deal Investment

13. Bristol-Myers Squibb

  • 13.1. Key Business and Therapy Areas
  • 13.2. Overview of Dealmaking
  • 13.3. M&A Activity
    • 13.3.1. Key M&A Deals
    • 13.3.2. Other Key M&A Deals
  • 13.4. Licensing Strategy and Deal Structures
    • 13.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 13.4.2. Therapy Area Focus by Sales
    • 13.4.3. Leading Therapy Areas in Dealmaking
    • 13.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 13.4.5. Comparison of Short- and Long-Term Deal Investment

14. Bayer

  • 14.1. Key Business and Therapy Areas
  • 14.2. Overview of Dealmaking
  • 14.3. M&A Activity
    • 14.3.1. Key M&A Deals
    • 14.3.2. Other Key M&A Deals
  • 14.4. Licensing Strategy and Deal Structures
    • 14.4.1. How Does the Company's Dealmaking Compare with its Peer Group
    • 14.4.2. Therapy Area Focus by Sales
    • 14.4.3. Leading Therapy Areas in Dealmaking
    • 14.4.4. Total and Average Upfront Values of Top Therapy Areas
    • 14.4.5. Comparison of Short- and Long-Term Deal Investment

Tables

  • 1.1. Definition of the indications used in the report
  • 1.2. Definition of the CorpMETRx metrics used in the report
  • 2.1. Top 12 pharmaceutical companies ranked by total number of M&A and Licensing deals over five year and 12 month periods.
  • 2.2. Five year and 12 month rankings of M&A activity of the top companies
  • 2.3. Five year and 12 month rankings of deal activity of the top companies
  • 2.4. Rankings of top companies 12 month licensing deal activity versus fi ve year patent risk
  • 2.5. Rankings of top companies 12 month licensing deal activity versus 2011 sales

Company-specific tables:

  • x.1. M&A activity and ranking vs peer group
  • x.2. Top M&A deals in the last 5 years by disclosed value
  • x.3. Overall licensing activity rankings
  • x.4. Top five therapy areas by percentage revenue in 2011 (Rx and OTC)
  • x.5. Therapy area activity
  • x.6. Top oncology deals by disclosed upfront payment
  • x.7. Short and long-term deal comparison
  • x.8.Top late stage deals by disclosed upfront payment
  • x.9 Top early stage deals by disclosed total deal value

Figures

  • 2.1. Total M&A and Licensing deal activities of the top companies
  • 2.2. M&A and Licensing deal volume over the last 12 months compared with the average 12 month deal volume over the last five years
  • 2.3. Five year and 12 month M&A activity of the top 12 companies
  • 2.4. M&A deal volume over the last 12 months compared with the average 12 month deal volume over the last five years
  • 2.5. Five-year mean M&A total deal values
  • 2.6. Five-year mean M&A total deal values without the mega mergers
  • 2.7. Five year and 12 month licensing deal activity of the top companies
  • 2.8. Licensing deal volume over the last 12 months compared with the average 12 month deal volume over the last five years
  • 2.9. Five year total licensing deal values for the top 12 companies
  • 2.10. Five year average total licensing deal values for the top 12 companies
  • 2.11. Five year total upfront payments for licensing deals of the top 12 companies
  • 2.12. Five year average upfront payments for licensing deals of the top 12 companies
  • 2.13. 12 Month licensing deal activity versus five year patent risk
  • 2.14. 12 Month licensing deal activity versus 2011 sales (Q2 2011 to Q1 2012)
  • 2.15. Percentage of deals completed by phase of development over a five year period
  • 2.16. Percentage of deals completed by phase of development over 12 month period
  • 2.17. Early stage deals by company
  • 2.18. Mid-stage deals by company
  • 2.19. Late stage deals by company
  • 2.20. Therapy area focus of the top companies
  • 2.21. Therapy area deal making as a proportion of the total licensing deals

Company-specific figures:

  • x.1. 2007-2012 Licensing and M&A deal activity
  • x.2. Deals vs Peers, deals/2011, deals/5 year patent risk
  • x.3. Deal activity in the company's lead therapy area by current sales
  • x.4. Therapy focus for dealmaking over the last 5 years
  • x.5. Oncology dealmaking against the competition
  • x.6. Total deal values of the top 5 therapy areas
  • x.7. Average upfront payments for the leading therapy areas
Back to Top